SCHEDULE: BlackRock Discloses Ginkgo Bioworks Stake

BlackRock, Inc. has amended its Schedule 13G filing to report its beneficial ownership of Ginkgo Bioworks Holdings, Inc. Class A Stock.

Summary

• BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting its beneficial ownership of Ginkgo Bioworks Holdings, Inc. Class A Stock.
• As of June 30, 2026, BlackRock beneficially owns 4,122,510 shares of Class A Stock, representing 7.7% of the class.
• This filing is an amendment to a previous filing, indicating a change or update in BlackRock's holdings.
• The filing specifies that BlackRock, Inc. is the reporting person, and its various business units are collectively considered the 'Reporting Business Units'.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It represents a standard disclosure of institutional ownership and does not inherently signal positive or negative performance for Ginkgo Bioworks.

Positives

• BlackRock, a significant institutional investor, has disclosed its holdings, which can be seen as a positive signal of confidence in Ginkgo Bioworks.
• The disclosure is clear and transparent, adhering to regulatory requirements.

Risks

• The filing does not contain specific forward-looking statements or risk factors beyond the standard disclosures inherent in a Schedule 13G filing.
• Potential for future changes in BlackRock's stake, which could impact Ginkgo Bioworks' stock price.

Future Outlook

This filing is a disclosure of current beneficial ownership and does not contain specific forward-looking statements or guidance from Ginkgo Bioworks Holdings, Inc.

Industry Context

StockSavvy.ai notes that Schedule 13G filings by large asset managers like BlackRock often signal significant institutional interest in a company. For Ginkgo Bioworks, a leader in synthetic biology, such disclosures can influence investor perception and potentially attract further institutional capital.

Stakeholder Impact

• Shareholders: The disclosure may influence investor sentiment and trading activity due to BlackRock's significant stake.
• Ginkgo Bioworks Management: The filing confirms a major institutional investor's position, which can be a positive indicator for future strategic discussions or capital needs.

Next Steps

• Monitor future filings from BlackRock for any changes in its beneficial ownership of Ginkgo Bioworks.
• Observe market reaction to this disclosure.

Key Dates

Recommendation

This filing is a disclosure of beneficial ownership by an institutional investor and does not provide performance data or strategic updates for Ginkgo Bioworks. Therefore, it does not offer sufficient information to warrant a buy or sell recommendation. A 'hold' is appropriate pending further operational or financial disclosures from the company.

Keywords

Ginkgo Bioworks, BlackRock, Schedule 13G, Institutional Investor, Beneficial Ownership, Class A Stock, SEC Filing, Investment